Abstract
Background: Cytarabine (ara-C) is the major drug for the treatment of acute myeloid leukemia (AML), but cellular resistance to ara-C is a major obstac......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
